Skip to main content
. 2016 Jul 1;7(31):50290–50301. doi: 10.18632/oncotarget.10366

Figure 8. Assessment of the therapeutic benefit of adding irinotecan or cetuximab to alisertib.

Figure 8

Tumors were individually modeled in order to quantitatively assess the in vivo combinatorial effects of adding alisertib to standard of care agents. ψ is the term used in the mathematical model to define the degree of interaction. ψ values of 1 represent an additive effect, ψ > 1 represent a synergistic effect, 0 < ψ < 1 represent a less-than-additive effect, and ψ < 0 represent an antagonistic effect.